• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SRI International, Nobelpharma partner on endometriosis treatment

SRI International, Nobelpharma partner on endometriosis treatment

September 11, 2014
CenterWatch Staff

SRI International, a California-based independent nonprofit research institute, and Nobelpharma, a Japanese pharmaceutical company, have entered into a licensing agreement to test SR16234, an SRI drug candidate that may be effective in treating endometriosis. SR16234 is a member of a class of drugs known as selective estrogen receptor modulators (SERMs) that regulate the effects of the hormone estrogen.

"This important collaboration is addressing a critical, unmet medical need, and we are doing so via a novel therapeutic approach targeting the underlying biological mechanisms of endometriosis," said Walter H. Moos, Ph.D., vice president of SRI Biosciences.

Jin Shiomura, Nobelpharma president and CEO, said, "After upcoming preliminary studies are completed, we hope to advance SR16234 into clinical trials in Japan for the treatment of endometriosis."

Endometriosis is a chronic disease that occurs when cells that line the uterus or womb grow elsewhere in the body. This misplaced tissue responds to hormonal changes and causes internal bleeding and inflammation that can lead to pain, scar tissue formation and infertility. According to the World Endometriosis Research Foundation, endometriosis affects approximately 176 million women worldwide.

"Currently available endometriosis treatments often address only the symptoms, such as pain and infertility, and not the underlying causes of the disease," said Krishna Kodukula, Ph.D., executive director of strategic development at SRI Biosciences. "There is a clear need for something better."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing